Synthesis and Biological Evaluation of 2-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)benzo[d]thiazole Derivatives as EGFR Targeting Anticancer Agents
作者:Boda Mahipal Reddy、Midde Sridhar、Mekala Himabindu、K. Bhaskar、G. V. R. Sai Madhukar、T. Karunakar、Sudhakar Reddy Baddam、Mamatha Kasula
DOI:10.1134/s1068162024020146
日期:2024.4
silico molecular docking studies. Results and Discussion: Compounds 2-(6-(4-chlorophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)benzo[d]thiazole (Vb), 2-(6-(4-bromophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)benzo[d]thiazole (Vd), and 2-(6-(4nitrophenyl)imidazo[2,1-b][1,3,4]thiadiazol-2-yl)benzo[d]thiazole (Vh) exhibited the most potent anticancer activity against MCF-7 and A549 cancer cell lines. Molecular
摘要 活性:苯并噻唑和咪唑并[2,1- b ][1,3,4]噻二唑衍生物是最重要的药效基团和制备药物的中间体。本研究重点关注新型苯并噻唑基咪唑并[2,1- b ][1,3,4]噻二唑支架的制备及其抗癌活性。方法:对合成的苯并噻唑基咪唑并[2,1- b ][1,3,4]噻二唑支架(Va-Vi)进行评估。 ( Va–Vi ) 针对 MCF-7 和 A549 细胞系的抗癌活性是使用 MTT 测定确定的,并通过计算机分子对接研究进行筛选。结果与讨论:化合物 2-(6-(4-氯苯基)咪唑并[2,1- b ][1,3,4]噻二唑-2-基)苯并[ d ]噻唑 ( Vb )、2-(6- (4-溴苯基)咪唑并[2,1- b ][1,3,4]噻二唑-2-基)苯并[ d ]噻唑( Vd )和2-(6-(4硝基苯基)咪唑[2,1-] b ][1,3,4]噻二唑-2-基)苯并[ d ]噻唑 ( Vh ) 对 MCF-7